Products with Antithrombotic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1009 | Ligustrazine Hydrochloride |
| Ligustrazine hydrochloride has antithrombotic effect, has certain protection effect on the vascular endothelium undergoing cardiopulmonary bypass (CPB), and can inhibit the activation of humai platelet following severe brain injury , improve t'ie balance, of TXA2 - PGI2 within the circulatory blood. It can exert down-regulate effects on Colon26 secretion of immunosuppressors and its tumor immunosuppression. | |
| BCN1044 | Atractylenolide II |
| Atractylenolide II has antiinflammatory activity, it can inhibit platelets activities and thrombus formation. Atractylenolide II has cytotoxic/apoptotic effects may via p38 activation ,ERK and Akt inactivation, p53 dependent, it also has antimelanoma effect by inhibiting STAT3 signalling. | |
| BCN1066 | Ginsenoside Rg1 |
| Ginsenoside Rg1 has antiaging, anti-platelet activation, promotion of wound healing, and neuroprotective effects, it has protective effect against Aβ25-35-induced toxicity in PC12 cells,might be through the insulin-like growth factor-I receptor (IGF-IR) and estrogen receptor (ER)signaling pathways. Ginsenoside Rg1 is a desirable agent for enhancing CD4+ T-cell activity, as well as the correction of Th1-dominant pathological disorders, which by increasing Th2 specific cytokine secretion and by repressing Th1 specific cytokine production. It increased the expression of the vascular endothelial growth factor (VEGF) mRNA and reduced ERK pathway, expression of transforming growth factor beta (TGF-β) mRNA. | |
